Biosketch Laura Soucek

Biosketch Laura Soucek
Laura Soucek VHIO
Laura Soucek
lsoucek@vhio.net
LinkedIn
Lloc actual
  • Codirectora del Programa de recerca preclínic i traslacional de VHIO
  • Cap de grup, Grup de Modelització de Teràpies Antitumorals del VHIO
  • Professora investigadora d’ICREA des del 2014
  • Professora associada del Departament de Bioquímica i Biologia Molecular de la Universitat Autònoma de Barcelona (UAB) des del 2015
  • Fundadora i directora general (CEO) de Peptomyc, SL des del 2014
Honors i filiacions
  • Editora científica de Cancer Discovery
  • Revisora de la revista Frontiers in Oncology – Molecular and Cellular Oncology
  • Revisora d’Anti-cancer Drugs, BBA (Biochimica et Biophysica Acta), Biodrugs, BioEssays,  Cancer Discovery, Cancer Immunology and Immunotherapy, Cancer Immunology Research, Cancer Research, Cancer Treatment Reviews, Clinical Cancer Research, Current Pharmaceutical Design, Developmental Dynamics, Drug Discovery Today, E-Biomedicine, eLIFE, Frontiers in Oncology, Gastroenterology Research and Practice, Gut, International Journal of Biological Sciences, IJEP (International Journal of Experimental Pathology), Journal of Cellular Biochemistry (JCB), Journal of Experimental and Clinical Cancer Research, JoVE Peer Reviewed Scientific Video Journal – Methods and Protocols, Medicinal Research Reviews, Molecular Biology and Evolution, Molecular Biology Reports, Molecular Oncology, Nature, Nature Cell Biology, Nature Communications, Nature Medicine, Oncogene, Oncogenesis, Oncology books (iConcept Press Ltd), Oncotarget, Peptide Science, Plos One, Science Translational Medicine, Scientific Reports, Therapeutic Advances in Chronic Disease i Tumor Biology.
  • Editora del llibre: The Myc gene: methods and protocols, col·lecció Methods in Molecular Biology (Humana Press).
Formació acadèmica
  • 2015 – actualitat: professora associada del Departament de Bioquímica i Biologia Molecular de la Universitat Autònoma de Barcelona (UAB)
  • 2014 – actualitat: professora investigadora d’ICREA
  • 2006-2011: biòloga molecular, investigadora assistent a la UCSF, San Francisco, Califòrnia (investigador principal: professor Gerard Evan), EUA.
  • 2003-2006: becària postdoctoral a l’Institut de Recerca Oncològica, UCSF, San Francisco, Califòrnia (investigador principal: professor Gerard Evan), EUA.
  • 2002-2003: biòloga molecular a l’IBPM (Institut de Biologia Molecular i Patologia), CNR, Roma (supervisor: Dr. Sergio Nasi), Itàlia
  • 2001-2002: becària postdoctoral al Centre Oncològic Integral, UCSF, San Francisco, Califòrnia (investigador principal: professor Gerard Evan), EUA.
  • 2001: doctorat en Genètica i Biologia Molecular a la Universitat La Sapienza, Roma, Itàlia.
  • 1997-1998: becària de Biologia Molecular al Centre d’Àcids Nucleics, CNR, Universitat La Sapienza, Roma, Itàlia.
  • 1996: llicenciatura en Ciències Biològiques amb matrícula d’honor a la Universitat La Sapienza, Roma, Itàlia.
Àrees de recerca
  • Inhibició del Myc i la seva validació com a teràpia eficaç contra el càncer
  • Disseny i prova d’inhibidors de Myc basats en Omomyc clínicament viables
  • Desenvolupament de models preclínics de teràpia contra el càncer
  • Immunodepressió relacionada amb el càncer
Premis i beques
  • Els seus mèrits científics i empresarials també han estat reconeguts per la marca de roba i equipament esportiu NIKE  a Barcelona, que la va seleccionar a ella i a Marie-Eve Beaulieu (primera autora de l’article «Science Translational Medicine» el 2019) com a talents de referència per a la ciència en el llançament de la seva campanya de màrqueting amb el FC Barcelona 2019.
  • Va rebre el Premi Europeu per a Dones Empresàries de l’Associació Europea d’Economia i Competitivitat i va guanyar el Premi FIDEM (Fundació Internacional per a Dones Empresàries) en la categoria de ciència.
  • Subvenció de prova de concepte de l’ERC (Comissió Europea). Títol: «Developing an anti-Myc cell-penetrating peptide for cancer treatment» (desenvolupament d’un pèptid anti-Myc de penetració cel·lular per al tractament del càncer). 2016-2017. Funcions: investigadora principal
  • Peptomyc va rebre una subvenció de l’Agència Catalana de Comerç i Inversions (ACCIÓ) per al projecte «Desenvolupament preclínic d’OmomycCPP: caracterització de la resposta immunitària». 2016. Funcions: investigadora principal
  • Peptomyc va rebre un «Segell d’Excel·lència» i un Instrument PIME Fase I de la Comissió Europea en el marc del Programa Horitzó 2020. Títol: «Feasibility study of a novel treatment for cancer based on a recombinant peptide therapy» (estudi de viabilitat d’un nou tractament contra el càncer basat en una teràpia peptídica recombinant). 2016. Funcions: investigadora principal
  • Beca de la Fundació BBVA en Biomedicina. Títol: «Validation of an innovative anti-Myc therapy in glioblastoma» (validació d’una innovadora teràpia anti-Myc en el glioblastoma). 2015-2017. Funcions: investigadora principal
  • Beca FERO per a un projecte de nanotecnologia: «Tractament del càncer de mama metastàtic amb nanopartícules basades en Omomyc». 2015-2016. Funcions: investigadora principal
  • Subvenció al Grup de Recerca Emergent de Catalunya de l’Agència de Gestió d’Ajuts Universitaris i de Recerca (AGAUR). 2014-2016. Funcions: investigadora principal
  • Consolidator Grant de l’ERC (Comissió Europea). Títol: «Pushing Myc inhibition towards the clinic» (impulsant la inhibició de Myc cap a la clínica). 2014-2019. Funcions: investigadora principal
  • Institut de Salut Carlos III: Projectes FIS de Recerca en Salut. Títol: «Advancing Myc inhibition towards clinic for the treatment of lung cancer» (avenç en la inhibició de Myc cap a la clínica per al tractament del càncer de pulmó). 2014-2017. Funcions: investigadora principal
  • Beca de l’Associació per a la Recerca Internacional del Càncer (AICR). Títol: «Advancing Myc inhibition towards the clinic: characterization of an Omomyc cell-penetrating peptide» (avenç en la inhibició de Myc cap a la clínica: caracterització d’un pèptid Omomyc de penetració cel·lular). 2013-2016. Funcions: investigadora principal
  • 2015: Primer premi del Concurs d’Innovació del VHIR, Barcelona, Espanya. Títol: «Pushing Myc inhibition to the clinic using cell penetrating peptides» (portar la inhibició de Myc a la clínica mitjançant pèptids de penetració cel·lular). El projecte pretén desenvolupar una nova opció terapèutica per a pacients amb càncer dirigint-se a la proteïna Myc amb un pèptid inhibidor, Omomyc, una nova entitat farmacèutica. Funcions: investigadora principal
    2013-2014: Iniciativa «Grants4Targets» de Bayer. Títol: «Pushing Myc inhibition towards the clinic» (impulsant la inhibició de Myc cap a la clínica).
  • Beca FERO. Projecte: «Atacar Myc en tumors i el seu microambient». 2011-2013. Funcions: investigadora principal
  • Beca Miguel Servet del FIS, Ministeri de Sanitat i Consum. Projecte «Inhibició de la resposta inflamatòria depenent del Myc i el Myc en tractaments del càncer». 2011-2014. Funcions: investigadora principal
  • Fundació de Pediàtrica del Càncer Bear Necessities: beca concedida per donar suport a un jove investigador excepcional en la recerca en càncer pediàtric. Tema: modelatge del potencial terapèutic del Myc in vivo. 2009. Funcions: investigadora principal
  • Premi AACR «Líders futurs, noves direccions» per a científics precoços destacats en la recerca sobre el càncer. 2008
  • Beca Keystone Symposia. 2007
  • Beca de recerca de la Fondazione Adriano Buzzati-Traverso, Roma (Itàlia): premi per a estudiants postdoctorals en biologia oncològica. Tema: el paper de Myc com a activador i repressor de la transcripció. 2002
  • Beca postdoctoral del CNR, Roma (Itàlia): premi pensat per cobrir el salari dels joves investigadors que vulguin adquirir experiència en recerca a un país estranger. Objectiu: disseny de dos models de ratolí diferents que expressin un transgèn Myc dominant negatiu, Omomyc. 2001
  • Beca de recerca de l’Associazione Italiana Ricerca sul Cancro (AIRC), Roma (Itàlia): premi per a joves investigadors en biologia oncològica. Tema: interferència de l’efecte del Myc sobre l’estructura de la cromatina. 2001
  • Beca del Centro Nazionale di Ricerca (CNR) per a estudiants de doctorat, Roma (Itàlia): premi per a estudiants del programa de doctorat en Genètica i Biologia Molecular. Tema: disseny d’un Myc dominant negatiu per ser utilitzat en línies cel·lulars tumorals. 1998
  • Beca de recerca per a estudiants de postgrau de la Fondazione Adriano Buzzati-Traverso, Roma (Itàlia): premi predoctoral de biologia oncològica. L’objectiu principal d’aquest projecte era investigar l’especificitat de dimerització de les proteïnes bHLHZip. 1997.
  • Premi de l’Agenzia per il Diritto agli Studi Universitari (ADISU) en reconeixement als millors estudiants de ciències matemàtiques, físiques i naturals, Roma (Itàlia). 1995
Projects
  1. Chiara Giorgetti Award from the Spanish Association of Metastatic Breast Cancer. Title: “Combining MYC and PARP inhibitors as a novel therapeutic strategy against triple-negative breast cancer”. 2022-2024. PI: Laura Soucek.
  2. 2nd BBVA Foundation Comprehensive Program of Cancer Immunotherapy & Immunology (CAIMI II), VHIO-FBBVA Collaboration. Title: “Understanding the tumor microenvironment to identify therapeutic targets and improve the response to immune checkpoint inhibitors” and “Understanding the mechanisms of resistance to IT and immune evasion to targeted therapies and designing new rational combinatory treatments”. 2022-2025. PI: Laura Soucek.
  3. Grant “I+D+I en Líneas Estratégicas en colaboración público-privada” from the Spanish Ministry of Economy, Industry and Competitiveness. Title: “Using MYC inhibition to overcome immunotherapy resistance in KRAS-driven NSCLC with diverse mutational profiles (MYCOMBIO)”. 2021-2024. PI: Laura Soucek.
  4. Project Title: Identification of clinical biormakers of response to MYC inhibition in cancer treatment.
    Principal Investigators: Laura Soucek
    Funding Agency: Spanish Ministry of Economy, Industry and Competitiveness “Retos de Colaboración” Grant.
    Duration: 2020-2023
  5. Project Title: Validation of new anti-Myc therapy in Melanoma.
    Principal Investigators: Laura Soucek
    Funding Agency: Instituto de Salud Carlos III: Proyectos FIS de Investigación en Salud.
    Duration: 2020-2022
  6. Project Title: Overcoming immunotherapeutic resistance through Myc inhibition in KRas-driven NSCLC with diverse mutational landscape.
    Principal Investigators: Laura Soucek. Co-participant: Silvestre Vicent Cambra.
    Funding Agency: Fundació La Marató de TV3.
    Duration: 2020-2022
  7. Project Title: Development of cancer therapies targeting Myc with cell penetrating b-HLH-LZ domains.
    Co-applicant
    Funding Agency: Canadian Institutes of Health Research Grant.
    Duration: 2018-2023
  8. H2020 INFRAIA 2017
    Grant: EDIReX: EurOPDX Distributed Infrastructure for Research on patient-derived cancer Xenografts.
    2017-2021.
    Role: Co-applicant
Most relevant scientific publications
  • Daniel Capitán LeoKaur, J, Soucek, L. Going for a “KDIP” in colorectal cancer treatment. Clin Transl Disc. 2022; 2:e108.
  • Massó-Vallés D, Beaulieu ME, Jauset T, Giuntini F, Zacarías-Fluck MF, Foradada L, Martínez-Martín S, Serrano E, Martín-Fernández G, Casacuberta-Serra S, Castillo Cano V, Kaur J, López-Estévez S, Morcillo MÁ, Alzrigat M, Mahmoud L, Luque-García A, Escorihuela M, Guzman M, Arribas J, Serra V, Larsson LG, Whitfield JR, Soucek L. MYC Inhibition Halts Metastatic Breast Cancer Progression by Blocking Growth, Invasion, and Seeding. Cancer Res Commun. 2022 Feb 21;2(2):110-130.
  • Mariano F. Zacarías-Fluck, Toni Jauset, Sandra Martínez-Martín, Jastrinjan Kaur, Sílvia Casacuberta-Serra, Daniel Massó-Vallés, Erika Serrano del Pozo, Génesis Martín-Fernández, Íñigo González-Larreategui, Sergio López-Estévez, Lamorna Brown-Swigart, Marie-Eve Beaulieu, Jonathan R. Whitfield, Babita Madan, David M. Virshu4, Gerard I. Evan and Laura Soucek. The Wnt signaling receptor Fzd9 is essential for Myc-driven tumorigenesis in pancreatic islets. Life Sci Alliance. 2021 Mar;4(5). DOI: 10.26508/lsa.2019004902021. Article.
  • Paola Pellanda, Mattia Dalsass, Marco Filipuzzi, Alessia Loffreda, Alessandro Verrecchia, Virginia Castillo Cano, Hugo Thabussot, Mirko Doni, Marco J. Morelli, Laura Soucek, Theresia Kress, Davide Mazza, Marina Mapelli, Marie-Eve Beaulieu, Bruno Amati and Arianna Sabò. Integrated requirement of non-specific and sequence-specific DNA binding in MYC-driven transcription. EMBO J. 2021. DOI: 10.15252/embj.2020105464. Article.
  • Beaulieu ME, Castillo F, Soucek L. Structural and Biophysical Insights into the Function of the Intrinsically Disordered Myc Oncoprotein. Cells. 2020 Apr22;9(4):1038.
  • Massó-Vallés D, Soucek L. Blocking Myc to Treat Cancer: Reflecting on Two Decades of Omomyc. Cells. 2020 Apr 4;9(4):883. doi: 10.3390/ cells9040883.PMID: 32260326
  • Massó-Vallés D, Beaulieu ME, Soucek L. MYC, MYCL, and MYCN as therapeutic targets in lung cancer. Expert Opin Ther Targets. 2020 Feb;24(2):101-114.
  • Sodir NM, Kortlever RM, Barthet VJA, Campos T, Pellegrinet L, Kupczak S, Anastasiou P,
  • Swigart LB, Soucek L, Arends MJ, Littlewood TD, Evan GI. MYC Instructs and Maintains Pancreatic Adenocarcinoma Phenotype. Cancer Discov. 2020 Apr;10(4):588-607.
  • Beaulieu ME, Jauset T, Massó-Vallés D, Martínez-Martín S, Rahl P, Maltais L, Zacarias-Fluck MF, Casacuberta-Serra S, Serrano del Pozo E, Fiore C, Foradada L, Castillo Cano V, Guenther M, Romero Sanz E, Oteo M, Tremblay C, Martín G, Letourneau D, Montagne M, Morcillo Alonso MA, Whitfield JR, Lavigne P, Soucek L. Intrinsic cell-penetrating activity propels Omomyc from proof of concept to viable anti-Myc therapy. Sci Trans Med. 2019 Mar 20;11(484).
  • Beaulieu ME, Soucek L. Finding MYCure. Mol Cell Oncol. 2019 Jun 20;6(5):e1618178.
  • Pesarrodona M, Jauset T, Díaz-Riascos ZV, Sánchez-Chardi A, Beaulieu ME, Seras-Franzoso J, Sánchez-García L, Baltà-Foix, Sandra Mancilla R, Fernández Y, Rinas U, Schwartz Jr S, Soucek L, Villaverde A, Abasolo I, Vázquez E. Targeting antitumoral proteins to breast cancer by local administration of functional inclusion bodies. Adv Sci. 2019 Jul 24.
  • Whitfield JR, Soucek L. Editorial Overview: Peptides in Cancer. Curr Opin Pharmacol. 2019 Jun 27. pii: S1471-4892(19)30045-1.
  • Massó-Vallés D, Jauset T, Soucek L. Ibrutinib repurposing: from B cell malignancies to solid tumors. Oncoscience. 2016 Jun 10;3(5-6):147-8.
  • Fiorentino FP, Tokgün E, Solé-Sánchez S, Giampaolo S, Tokgün O, Jauset T, Kohno T, Perucho M, Soucek L, Yokota J. Growth Suppression by MYC Inhibition in Small Cell Lung Cancer Cells with TP53 and RB1 Inactivation.  Oncotarget. 2016 May 24;7(21):31014-28.
  • Daniel Massó-Vallés, Toni Jauset and Laura Soucek. Ibrutinib repurposing: from B cell malignancies to solid tumors. Oncoscience. Onlibe Advanced Publication DOI: 10.18632/oncoscience.310. Editorial.
  • Francesco Paolo Fiorentino, Elvan Tokgün, Sònia Solé-Sánchez, Sabrina Giampaolo, Onur Tokgün, Toni Jauset, Takashi Kohno, Manuel Perucho, Laura Soucek, Jun Yokota. Growth Suppression by MYC Inhibition in Small Cell Lung Cancer Cells with TP53 and RB1 Inactivation. Oncotarget. 2016 Apr 18. doi: 10.18632/oncotarget.8826. [Epub ahead of print] Article.
  • Stephanie C. Casey, Monica Vaccari, Fahd Al-Mulla, Rabeah Al-Temaimi, Amedeo Amedei, Mary Helen Barcellos-Hoff, Dustin Brown, Marion Chapellier, […], Sandra Ryeom, Hosni K. Salem, Ivana Scovassi,  Neetu Singh, Laura Soucek, Louis Vermeulen, Jonathan R. Whitfield, Jordan Woodrick, Annamaria Colacci, William H. Bisson, and Dean W. Felsher. Assessing the Carcinogenic Potential of Environmental Chemicals: The Tumor Microenvironment. Carcinogenesis. 2015 Jun;36 Suppl 1:S160-83. Review.
  • Daniel Massó-Vallés, Toni Jauset, Erika Serrano, Nicole M. Sodir, Kim Pedersen, Nesrine I. Affara, Jonathan R. Whitfield, Marie-Eve Beaulieu, Gerard I. Evan, Laurence Elias, Joaquín Arribas and Laura Soucek. Ibrutinib exerts potent anti-fibrotic and anti-tumor activity in mouse transgenic and patient derived xenograft models of pancreatic adenocarcinoma. Cancer Res. 2015 Apr 15; 75(8): 1675-1681. Article.
  • Daniela Annibali, Jonathan R Whitfield, Emilia Favuzzi, Toni Jauset, Erika Serrano, Isabel Cuartas, Sara Redondo-Campos, Gerard Folch, Alba Gonzàlez-Juncà, Nicole M Sodir, Daniel Massó-Vallés, Marie-Eve Beaulieu, Lamorna B Swigart, Margaret M Mc Gee, Maria Patrizia Somma, Sergio Nasi, , Joan Seoane, Gerard I Evan, and Laura Soucek. Myc Inhibition as a Therapeutic Strategy Against Glioma: a Role for Myc in Proficient Mitosis. Nat Communications. 2014 Aug 18;5:4632. Article.
  • Laura Soucek, Jonathan R. Whitfield, Nicole M. Sodir, Daniel Massó-Vallés, Erika Serrano, Anthony N. Karnezis, Lamorna Brown Swigart and Gerard I. Evan. Inhibition of Myc family proteins eradicates KRas-driven lung cancer in mice. Genes Dev. 2013 Mar 1;27(5):504-13. Article.
  • Whitfield J, Soucek L. Tumor microenvironment: becoming sick of Myc. Cell Mol Life Sci. 2012, 69(6), 931-934. Review.
  • Nicole M Sodir, Lamorna Brown Swigart, Anthony N Karnezis, Douglas Hanahan, Gerard Evan and Laura Soucek. Endogenous Myc maintains the tumor microenvironment. Genes Dev. 2011 May 1;25(9):907-16. Epub 2011 Apr 8. Article.
  • Andrew Finch*, Laura Soucek*, Melissa Junttila, Lamorna Brown Swigart and Gerard I. Evan. Acute over-expression of Myc in intestinal epithelium recapitulates some but not all the changes elicited by Wnt/β-catenin pathway activation. Mol Cell Biol. 2009 Oct;29(19):5306-15. Epub 2009 Jul 27. Article. *Joint first authors
  • Laura Soucek, Jonathan Whitfield, Carla P. Martins, Andrew J. Finch, Nicole M. Sodir, Lamorna Brown Swigart, Sergio Nasi and Gerard I. Evan. Modelling Myc inhibition as a cancer therapy. Nature. 2008 Oct 2;455(7213):679-83. Epub 2008 Aug 17. Article.
  • Soucek L, Lawlor ER, Soto D, Shchors K, Swigart LB, Evan GI. Mast cells are required for angiogenesis and macroscopic expansion of Myc-induced pancreatic islet tumors. Nat Med. 2007 Oct;13(10):1211-8. Epub 2007 Sep 30. Article.
  • Maria A. Christophorou, Dionisio Martin-Zanca, Laura Soucek, Elizabeth Lawlor, Emmy Verschuren, Lamorna Brown-Swigart and Gerard I. Evan. Temporal dissection of p53 function in vitro and in vivo.Nature Genetics. 2005 Jul;37(7):718-26. Article.
  • Laura Soucek, Sergio Nasi, and Gerard Evan. Omomyc expression in skin prevents Myc-induced papillomatosis. Cell Death Differ. 2004 Sep;11(9):1038-45. Article.
  • Laura Soucek and Gerard Evan. Myc – is this the oncogene from Hell?. Cancer Cell. 2002 June; 1(5): 406-408. Review.
  • Laura Soucek, Richard Jucker, Laura Panacchia, Ruggero Ricordy, Franco Tatò, and Sergio Nasi. Omomyc, a Potential Myc Dominant Negative, Enhances Myc-induced Apoptosis. Cancer Res. 2002; 62: 3507-3510. Article.
  • Soucek L., Citterich M.H., Sacco A., Jucker R., Cesareni G. and Nasi S. Design and properties of a Myc derivative that efficiently homodimerizes. Oncogene. 1998, 17(19): 2463-2472. Article.
All publications
  • Daniel Capitán LeoKaur, J, Soucek, L. Going for a “KDIP” in colorectal cancer treatment. Clin Transl Disc. 2022; 2:e108.
  • Massó-Vallés D, Beaulieu ME, Jauset T, Giuntini F, Zacarías-Fluck MF, Foradada L, Martínez-Martín S, Serrano E, Martín-Fernández G, Casacuberta-Serra S, Castillo Cano V, Kaur J, López-Estévez S, Morcillo MÁ, Alzrigat M, Mahmoud L, Luque-García A, Escorihuela M, Guzman M, Arribas J, Serra V, Larsson LG, Whitfield JR, Soucek L. MYC Inhibition Halts Metastatic Breast Cancer Progression by Blocking Growth, Invasion, and Seeding. Cancer Res Commun. 2022 Feb 21;2(2):110-130.
  • Kaur, J, Soucek, L. Going for a “KDIP” in colorectal cancer treatment. Clin Transl Disc. 2022; 2:e108.
  • Massó-Vallés D, Beaulieu ME, Jauset T, Giuntini F, Zacarías-Fluck MF, Foradada L, Martínez-Martín S, Serrano E, Martín-Fernández G, Casacuberta-Serra S, Castillo Cano V, Kaur J, López-Estévez S, Morcillo MÁ, Alzrigat M, Mahmoud L, Luque-García A, Escorihuela M, Guzman M, Arribas J, Serra V, Larsson LG, Whitfield JR, Soucek L. MYC Inhibition Halts Metastatic Breast Cancer Progression by Blocking Growth, Invasion, and Seeding. Cancer Res Commun. 2022 Feb 21;2(2):110-130.
  • Mariano F. Zacarías-Fluck, Toni Jauset, Sandra Martínez-Martín, Jastrinjan Kaur, Sílvia Casacuberta-Serra, Daniel Massó-Vallés, Erika Serrano del Pozo, Génesis Martín-Fernández, Íñigo González-Larreategui, Sergio López-Estévez, Lamorna Brown-Swigart, Marie-Eve Beaulieu, Jonathan R. Whitfield, Babita Madan, David M. Virshu4, Gerard I. Evan and Laura Soucek. The Wnt signaling receptor Fzd9 is essential for Myc-driven tumorigenesis in pancreatic islets. Life Sci Alliance. 2021 Mar;4(5). DOI: 10.26508/lsa.2019004902021. Article.
  • Paola Pellanda, Mattia Dalsass, Marco Filipuzzi, Alessia Loffreda, Alessandro Verrecchia, Virginia Castillo Cano, Hugo Thabussot, Mirko Doni, Marco J. Morelli, Laura Soucek, Theresia Kress, Davide Mazza, Marina Mapelli, Marie-Eve Beaulieu, Bruno Amati and Arianna Sabò. Integrated requirement of non-specific and sequence-specific DNA binding in MYC-driven transcription. EMBO J. 2021. DOI: 10.15252/embj.2020105464. Article.
  • Beaulieu ME, Castillo F, Soucek L. Structural and Biophysical Insights into the Function of the Intrinsically Disordered Myc Oncoprotein. Cells. 2020 Apr 22;9(4). pii: E1038. doi: 10.3390/cells9041038. Review.
  • Massó-Vallés D. and Soucek L. Blocking Myc to Treat Cancer: Reflecting on Two Decades of Omomyc. Cells. 2020, 9, 883; doi:10.3390/cells9040883. Review.
  • Daniel Massó-Vallés, Marie-Eve Beaulieu and Laura Soucek. “MYC, MYCL and MYCN as therapeutic targets in lung cancer”. Expert Opin Ther Targets. 2020 Jan 31. doi: 10.1080/14728222.2020.1723548. Review.
  • Nicole Sodir, Roderik Kortlever, Valentin Barthet, Tania Campos, Luca Pellegrinet, Steven Kupczak, Panayiotis Anastasiou, Lamorna Brown-Swigart, Laura Soucek, Mark Arends, Trevor Littlewood, and Gerard Evan. “Myc instructs and maintains pancreatic adenocarcinoma phenotype”. Cancer Discov. 2020 Jan 15. pii: CD-19-0435. doi: 10.1158/2159-8290.CD-19-0435. Article.
  • Rafael Ikemori, Marta Gabasa, Paula Duch, Miguel Vizoso, Paloma Bragado, Marselina Arshakyan, Iuliana-Cristiana Luis, Albert Marín, Sebastian Morán, Manuel Castro, Gemma Fuster, Sabrina Gea-Sorli, Toni Jauset, Laura Soucek, Luis Montuenga, Manel Esteller, Eduard Monsó, Víctor Ivo Peinado, Pere Gascón, Cristina Fillat, Frank Hilberg, Noemí Reguart, Jordi Alcaraz. “Epigenetic SMAD3 repression in tumor-associated fibroblasts impairs fibrosis and response to the antifibrotic drug nintedanib in lung squamous cell carcinoma”. Cancer Res. 2020 Jan 15;80(2):276-290. doi: 10.1158/0008-5472.CAN-19-0637. Article.
  • Mireia Pesarrodona, Toni Jauset, Zamira V. Díaz-Riascos, Alejandro Sánchez-Chardi, Marie-Eve Beaulieu, Joaquin Seras-Franzoso, Laura Sánchez-García, Ricardo Baltà-Foix, Sandra Mancilla, Yolanda Fernández, Ursula Rinas, Simó Schwartz Jr, Laura Soucek, Antonio Villaverde, Ibane Abasolo, and Esther Vázquez. “Targeting antitumoral proteins to breast cancer by local administration of functional inclusion bodies”. Advanced Sciences. Adv Sci (Weinh). 2019 Jul 24;6(18):1900849. doi: 10.1002/advs.201900849. Article.
  • Jonathan R. Whitfield and Laura Soucek. Editorial Overview: Peptides in Cancer. Current Opinion in Pharmacology. 2019 Jun 27. pii: S1471-4892(19)30045-1. Doi: 10.1016/j.coph.2019.06.001. Editorial.
  • Marie-Eve Beaulieu and Laura Soucek. Finding MYCure. Mol Cell Oncology. 2019. Doi: 10.1080/23723556.2019.1618178. Author’s View.
  • Ramón Y Cajal S, Sancho P, Soucek L, Peinado H, Abad M, Valiente M, Efeyan A, Pardo J, Quesada V, Jimeno J, Duque PM, Antón A, Varela I, Schuhmacher AJ. A spotlight on cancer researchers in Spain: new paradigms and disruptive ideas. Clin Transl Oncol. 2019 Aug 9. doi: 10.1007/s12094-019-02199-4.
  • Marie-Eve Beaulieu, Toni Jauset, Daniel Massó-Vallés, Sandra Martínez-Martín, Peter Rahl, Loïka Maltais, Mariano F. Zacarias-Fluck, Sílvia Casacuberta-Serra, Erika Serrano del Pozo, Christopher Fiore, Laia Foradada, Virginia Castillo Cano, Matthew Guenther, Eduardo Romero Sanz, Marta Oteo, Cynthia Tremblay, Génesis Martín, Danny Letourneau, Martin Montagne, Miguel Ángel Morcillo Alonso, Jonathan R. Whitfield, Pierre Lavigne and Laura Soucek. Intrinsic cell-penetrating activity propels Omomyc from proof of concept to viable anti-Myc therapy. Sci Trans Med. 2019 Mar 20;11(484). Doi: 10.1126/scitranslmed.aar5012. Article.
  • Irina Alimova, Angela Pierce, Etienne Danis, Andrew Donson, Diane K Birks, Andrea Griesinger, Nicholas K Foreman, Mariarita Santi, Laura Soucek, Sujatha Venkataraman & Rajeev Vibhakar. Inhibition of MYC attenuates tumor cell self-renewal and promotes senescence in SMARCB1 deficient Group 2 Atypical Teratoid Rhabdoid Tumors to suppress tumor growth in vivo. Int J Cancer. 2019 Apr 15;144(8):1983-1995. doi: 10.1002/ijc.31873. Article.
  • Sílvia Casacuberta-Serra and Laura Soucek. Myc and Ras, the Bonnie and Clyde of immune evasion. Translational Cancer Research. 2018 Feb ;7(Suppl 4):S457-S459. doi: 10.21037/tcr.2018.03.09. Editorial.
  • Toni Jauset, Daniel Massó-Vallés, Sandra Martínez-Martín, Marie-Eve Beaulieu, Laia Foradada, Francesco Paolo Fiorentino, Jun Yokota, Bernard Haendler, Stephan Siegel, Jonathan R. Whitfield and Laura Soucek. BET inhibition is an effective approach against KRAS-driven PDAC and NSCLC. Oncotarget. 2018 Apr 10;9(27):18734-18746. doi: 10.18632/oncotarget.24648. Article.
  • Chi Dang, E Premkumar Reddy, Kevan Shokat, and Laura Soucek. Drugging the ‘undruggable’ cancer targets. Nat Rev Cancer.  2017 Jun 23. doi: 10.1038/nrc.2017.36. Review.
  • Kim Pedersen, Faiz Bilal, Cristina Bernadó Morales, Maria Teresa Salcedo, Teresa Macarulla, Daniel Massó-Vallés, Vishnu Mohan, Ana Vivanco, Maria-Josep Carreras, Xavier Serres, Monder Abu-Suboh, Joaquim Balsells, Elena Allende, Irit Sagi, Laura Soucek, Josep Tabernero and Joaquín Arribas. Pancreatic cancer heterogeneity and response to Mek inhibition. Oncogene. 2017 Jun 5. doi: 10.1038/onc.2017.174. [Epub ahead of print]. Article.
  • Loïka Maltais, Martin Montagne, Mikaël Bédard, Cynthia Tremblay, Laura Soucek and Pierre Lavigne. Biophysical Characterization of the b-HLH-LZ of ΔMax, an Alternatively Spliced Isoform of Max Found in Tumor Cells: Towards the Validation of a Tumor Suppressor Role for the Max Homodimer. PLoS One. 2017 Mar 28; 12(3): e0174413. https://doi.org/10.1371/journal.pone.0174413. Article.
  • Jonathan R Whitfield, Marie-Eve Beaulieu, Laura Soucek. Strategies to inhibit Myc and their clinical applicability. Front. Cell Dev. Biol., 23 February 2017 | https://doi.org/10.3389/fcell.2017.00010. Review.
  • Annette T. Byrne, Denis G. Alférez, Frederic Amant, Daniela Annibali, Joaquín Arribas, Andrew V. Biankin, Alejandra Bruna,  Eva Budinská, Carlos Caldas, David K. Chang, Robert B. Clarke, Hans Clevers, George Coukos, Virginie Dangles-Marie, S. Gail Eckhard, Eva Gonzalez-Suarez, Els Hermans, Manuel Hidalgo, Monika Jarzabek, Steven de Jong, Jos Jonkers, Kristel Kemper, Luisa Lanfrancone, Gunhild Mari Mælandsmo, Elisabetta Marangoni, Jean-Christophe Marine, Enzo Medico, Jens Henrik Norum, Héctor G. Palmer, Daniel S. Peeper, Pier Giuseppe Pelicci, Alejandro Piris, Sergio Roman-Roman, Oscar M. Rueda, Joan Seoane, Violeta Serra, Laura Soucek, Dominique Vanhecke, Alberto Villanueva, Emilie Vinolo, Andrea Bertotti and Livio Trusolino. Interrogating open issues in cancer precision medicine using Patient-Derived Xenograft Models.  Nat Rev Cancer. 2017 Jan 20. doi: 10.1038/nrc.2016.140. [Epub ahead of print]. Review.
  • M.E. Beaulieu, T. Jauset, D. Massó-Vallés, L. Soucek* and J.R. Whitfield. Mouse Models in Personalized Cancer Medicine. Chapter 6 of Cancer genetics and Genomics for Personalized Medicine. 2017. ISBN: 9789814669887. Book Chapter. *Corresponding author.
  • Soucek L, Torrens L, Pujades C and Claría J. Experimental Models. Handbook of Translational Medicine. Medica UB. 2016. ISBN: 978-84-475-4030-3. Book chapter.
  • Daniel Massó-Vallés, Toni Jauset and Laura Soucek. Ibrutinib repurposing: from B cell malignancies to solid tumors. Oncoscience. 2016 Jun 10;3(5-6):147-8. DOI: 10.18632/oncoscience.310. Review.
  • Francesco Paolo Fiorentino, Elvan Tokgün, Sònia Solé-Sánchez, Sabrina Giampaolo, Onur Tokgün, Toni Jauset, Takashi Kohno, Manuel Perucho, Laura Soucek, Jun Yokota. Growth Suppression by MYC Inhibition in Small Cell Lung Cancer Cells with TP53 and RB1 Inactivation. Oncotarget. 2016 Apr 18. doi: 10.18632/oncotarget.8826. [Epub ahead of print] Article.
  • Cecconi F, Soucek L, Taub DD, Ziparo E. Live or Die: Choice Mechanisms in Stressed Cells. Mediators Inflamm. 2015; 2015:454863. Epub 2015 Oct 8. Editorial.
  • William H. Goodson III, Leroy Lowe, David O. Carpenter, Michael Gilbertson, Abdul Manaf Ali, Adela Lopez de Cerain Salsamendi, […], Laura Soucek, […], Zhiwei Hu. Assessing the Carcinogenic Potential of Low Dose Exposures to Chemical Mixtures in the Environment: The Challenge Ahead. Carcinogenesis. 2015 Jun;36 Suppl 1:S254-96. doi: 10.1093/carcin/bgv039. Review.
  • Stephanie C. Casey, Monica Vaccari, Fahd Al-Mulla, Rabeah Al-Temaimi, Amedeo Amedei, Mary Helen Barcellos-Hoff, Dustin Brown, Marion Chapellier, […], Sandra Ryeom, Hosni K. Salem, Ivana Scovassi, Neetu Singh, Laura Soucek, Louis Vermeulen, Jonathan R. Whitfield, Jordan Woodrick, Annamaria Colacci, William H. Bisson, and Dean W. Felsher. Assessing the Carcinogenic Potential of Environmental Chemicals: The Tumor Microenvironment. Carcinogenesis. 2015 Jun;36 Suppl 1:S160-83. doi: 10.1093/carcin/bgv035. Review.
  • Daniel Massó-Vallés, Toni Jauset, Erika Serrano, Nicole M. Sodir, Kim Pedersen, Nesrine I. Affara, Jonathan R. Whitfield, Marie-Eve Beaulieu, Gerard I. Evan, Laurence Elias, Joaquín Arribas and Laura Soucek. Ibrutinib exerts potent anti-fibrotic and anti-tumor activity in mouse transgenic and patient derived xenograft models of pancreatic adenocarcinoma. Cancer Res. 2015 Apr 15; 75(8): 1675-1681. Article.
  • Whitfield J, Littlewood T, Evan GI, Soucek L. The estrogen receptor fusion system in mouse models: a reversible switch. Cold Spring Harb Protoc. 2015 Mar 2;2015(3):pdb.top069815. doi: 10.1101/pdb.top069815. Book chapter.
  • Whitfield J, Littlewood T, Soucek L. Tamoxifen administration to mice. Cold Spring Harb Protoc. 2015 Mar 2;2015(3):pdb.prot077966. doi: 10.1101/pdb.prot077966. Book chapter.
  • Daniela Annibali, Jonathan R Whitfield, Emilia Favuzzi, Toni Jauset, Erika Serrano, Isabel Cuartas, Sara Redondo-Campos, Gerard Folch, Alba Gonzàlez-Juncà, Nicole M Sodir, Daniel Massó-Vallés, Marie-Eve Beaulieu, Lamorna B Swigart, Margaret M Mc Gee, Maria Patrizia Somma, Sergio Nasi, Joan Seoane, Gerard I Evan, and Laura Soucek. Myc Inhibition as a Therapeutic Strategy Against Glioma: a Role for Myc in Proficient Mitosis. Nat Communications. 2014 Aug 18;5:4632. doi: 10.1038/ncomms5632. Article.
  • Book: “The Myc gene”, Methods and Protocols, Series: Methods in Molecular Biology, Vol. 1012. Soucek, Laura; Sodir, Nicole M. (Editors) 2013. A product of Humana Press.
  • Nicole M. Sodir and Laura Soucek. Chapter: The Myc world within reach. “Myc: Methods and Protocols” Book, Methods Mol Biol. 2013;1012:1-6. Book chapter.
  • Laura Soucek, Jonathan R. Whitfield, Nicole M. Sodir, Daniel Massó-Vallés, Erika Serrano, Anthony N. Karnezis, Lamorna Brown Swigart and Gerard I. Evan. Inhibition of Myc family proteins eradicates KRas-driven lung cancer in mice. Genes Dev. 2013 Mar 1;27(5):504-13. Article.
  • Whitfield J, Soucek L. Tumor microenvironment: becoming sick of Myc. Cell Mol Life Sci. 2012, 69(6), 931-934. Review.
  • Oscar M. Pello, Maria De Pizzol, Massimiliano Mirolo, Laura Soucek, Luca Zammataro, Angelo Amabile, Andrea Doni, Lamorna B. Swigart, Gerard I. Evan, Alberto Mantovani, Massimo Locati. c-Myc controls alternative activation of human macrophages and tumor-associated macrophage biology. Blood. 2012, 119(2), 411-421. Article.
  • Laura Soucek, Joseph J Buggy, Roderik Kortlever, Shanthi Adimoolam, Lamorna Brown Swigart and Gerard Evan. Modeling mast cell inhibition by PCI-32765 as potential therapy for insulinoma. Neoplasia. 2011; 13(11):1093–100. Article.
  • Mauro Savino, Daniela Annibali, Nicoletta Carucci, Laura Soucek, Gerard Evan, Sergio Nasi. The Action Mechanism of the Myc Inhibitor Termed Omomyc May Give Clues on How to Target Myc for Cancer Therapy. PLoS One. 2011;6(7):e22284. Epub 2011 Jul 21. Article.
  • Nicole M Sodir, Lamorna Brown Swigart, Anthony N Karnezis, Douglas Hanahan, Gerard Evan and Laura Soucek. Endogenous Myc maintains the tumor microenvironment. Genes Dev. 2011 May 1;25(9):907-16. Epub 2011 Apr 8. Article.
  • Fukazawa T, Maeda Y, Matsuoka J, Yamatsuji T, Shigemitsu K, Morita I, Faiola F, Durbin ML, Soucek L, Naomoto Y. Inhibition of Myc effectively targets KRAS mutation-positive lung cancer expressing high levels of Myc. Anticancer Res. 2010 Oct;30(10):4193-200. Article.
  • Soucek L, Evan GI. The ups and downs of Myc biology. Curr Opin Genet Dev. 2010 Feb;20(1):91-95. Epub 2009 Dec 3. Review.
  • Andrew Finch*, Laura Soucek*, Melissa Junttila, Lamorna Brown Swigart and Gerard I. Evan. Acute over-expression of Myc in intestinal epithelium recapitulates some but not all the changes elicited by Wnt/β-catenin pathway activation. Mol Cell Biol. 2009 Oct;29(19):5306-15. Epub 2009 Jul 27. Article. *Joint first authors
  • Laura Soucek, Jonathan Whitfield, Carla P. Martins, Andrew J. Finch, Nicole M. Sodir, Lamorna Brown Swigart, Sergio Nasi and Gerard I. Evan. Modelling Myc inhibition as a cancer therapy. Nature. 2008 Oct 2;455(7213):679-83. Epub 2008 Aug 17. Article.
  • Soucek L, Lawlor ER, Soto D, Shchors K, Swigart LB, Evan GI. Mast cells are required for angiogenesis and macroscopic expansion of Myc-induced pancreatic islet tumors. Nat Med. 2007 Oct;13(10):1211-8. Epub 2007 Sep 30. Article.
  • Finch A, Prescott J, Shchors K, Hunt A, Soucek L, Dansen TB, Swigart LB, Evan GI. Bcl-x(L) gain of function and p19(ARF) loss of function cooperate oncogenically with Myc in vivo by distinct mechanisms. Cancer Cell. 2006 Aug;10(2):113-120. Article.
  • Elizabeth R. Lawlor, Laura Soucek, Lamorna Brown-Swigart, Ksenya Shchors, Uli Bialucha, Gerard I. Evan. Reversible Kinetic Analysis of Myc Targets In vivo Provides Novel Insights into Myc-Mediated Tumorigenesis. Cancer Res. 2006 May 1;66(9):4591-601. Article.
  • Maria A. Christophorou, Dionisio Martin-Zanca, Laura Soucek, Elizabeth Lawlor, Emmy Verschuren, Lamorna Brown-Swigart and Gerard I. Evan. Temporal dissection of p53 function in vitro and in vivo. Nature Genetics. 2005 Jul;37(7):718-26. Article.
  • Laura Soucek, Sergio Nasi, and Gerard Evan. Omomyc expression in skin prevents Myc-induced papillomatosis. Cell Death Differ. 2004 Sep;11(9):1038-45. Article.
  • Satoshi Kanasawa, Laura Soucek, Gerard Evan, Takashi Okamoto, and B. Matija Peterlin. c-Myc recruits P-TEFb for transcription, cellular proliferation and apoptosis. Oncogene. 2003 Aug 28;22(36):5707-11. Article.
  • Laura Soucek and Gerard Evan. Myc – is this the oncogene from Hell?. Cancer Cell. 2002 June; 1(5): 406-408. Review.
  • Laura Soucek, Richard Jucker, Laura Panacchia, Ruggero Ricordy, Franco Tatò, and Sergio Nasi. Omomyc, a Potential Myc Dominant Negative, Enhances Myc-induced Apoptosis . Cancer Res. 2002; 62: 3507-3510. Article.
  • Mandolesi G, Gargano S, Pennuto M, Illi B, Molfetta R, Soucek L, Mosca L, Levi A, Jucker R, Nasi S. NGF-dependent and tissue-specific transcription of vgf is regulated by a CREB-p300 and bHLH factor interaction. FEBS Lett. 2002. ¡ 510(1-2):50-6. Article.
  • Sergio Nasi, Roberta Ciarapica, Richard Jucker, Jessica Rosati and Laura Soucek. Making decisions through Myc. FEBS. 2001. 490(3): 153-162. Review.
  • Sergio Nasi and Laura Soucek. p53 Gene e Proteina, Enciclopedia Medica Italiana, Tomo III, 2000, 4313-4323. Book chapter.
  • Soucek L., Citterich M.H., Sacco A., Jucker R., Cesareni G. and Nasi S. Design and properties of a Myc derivative that efficiently homodimerizes. Oncogene. 1998, 17(19): 2463-2472. Article.
Privacy Preferences
When you visit our website, it may store information through your browser from specific services, usually in form of cookies. Here you can change your privacy preferences. Please note that blocking some types of cookies may impact your experience on our website and the services we offer.
Privacy Policy
You have read and agreed to our privacy policy
Required